Innate Pharma Sa Stock Price, News & Analysis

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced key presentations at the ESMO Annual Meeting 2022 in Paris from September 9-13. Highlights include:

• Poster Presentation: Ongoing Phase 1b trial of lacutamab for peripheral T-cell lymphoma.
• Oral Presentation: ANKET platform by Eric Vivier focusing on multispecific antibodies for NK cell activation.
• Mini Oral Presentation: AstraZeneca's Phase 2 NeoCOAST study on durvalumab in early-stage NSCLC.

Lacutamab targets KIR3DL2 expressed in certain aggressive lymphomas, showcasing Innate's innovative approaches in oncology.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced participation in investor conferences, including Citi's 17th Annual BioPharma Conference on September 7-8, 2022, and H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022. The company, focused on oncology, is advancing several first-in-class therapeutic antibodies aimed at enhancing cancer treatment outcomes. With a strong pipeline and partnerships with major biopharmaceutical leaders, Innate is committed to improving patient care in high unmet medical need areas.

Innate Pharma has released its total number of shares outstanding and voting rights as of August 1, 2022. The company has 79,893,019 ordinary shares and 6,514 preferred shares from 2016 and 7,581 from 2017. The total theoretical voting rights stand at 80,650,859, with exercisable voting rights at 80,632,284. This disclosure is in compliance with French regulations to ensure transparency for shareholders.

Innate Pharma announced that the INTERLINK-1 Phase 3 study, sponsored by AstraZeneca, did not meet the efficacy threshold during an interim analysis and will be discontinued. The trial evaluated monalizumab with cetuximab against cetuximab alone for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Despite this setback, Innate remains optimistic about monalizumab's potential in lung cancer and continues to focus on ongoing studies like PACIFIC-9 and NeoCOAST-2. AstraZeneca will share data from the trial in the future.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced participation in the upcoming BTIG Biotechnology Conference scheduled for August 8-9, 2022 in New York. The company is focused on developing therapeutic antibodies to improve oncology treatments. With a diverse pipeline of clinical and preclinical candidates, Innate is recognized for its expertise in Natural Killer cell biology and partnerships with major biopharmaceutical companies such as Bristol-Myers Squibb and AstraZeneca. For more information, visit www.innate-pharma.com.

Innate Pharma has announced that Sanofi is progressing IPH6401/SAR’514 into investigational new drug enabling studies, triggering a €3 million milestone payment. This BCMA-targeting NK cell engager utilizes Sanofi’s CROSSODILE platform, combined with Innate’s ANKET technology, to enhance NK cell activation for cancer therapy. IPH6401/SAR’514 has demonstrated anti-tumor activity in preclinical models, with Sanofi overseeing its development, manufacturing, and commercialization. The collaboration may yield up to €400 million in further development milestones and royalties for Innate.

Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced its participation in the Portzamparc Corporate Access event in Paris on June 30, 2022. The company is a clinical-stage biotech firm focused on oncology, aiming to improve cancer treatments through antibody therapies that utilize the immune system. Innate has a diverse pipeline of clinical candidates and partnerships with leading pharmaceutical companies, including Bristol-Myers Squibb and AstraZeneca. Headquartered in Marseille, France, Innate continues to advance its research and collaboration efforts.

Innate Pharma announced that its anti-CD39 monoclonal antibody, IPH5201, will advance to a Phase 2 clinical trial in lung cancer. The company will receive a $5M milestone payment from AstraZeneca (AZN), which will share study costs and supply clinical trial drugs. This trial showcases Innate's progress in building its late-stage pipeline. The IPH5201 antibody targets the immunosuppressive CD39 pathway, crucial in tumor biology. Innate's partnership with AstraZeneca includes multiple trials, indicating a strong collaboration.

Innate Pharma (Euronext: IPH; Nasdaq: IPHA) has announced the results of its Annual General Meeting (AGM) held on May 20, 2022, in Marseille, France. A quorum of 40.88% was reached with 134 votes cast from a total of 32,598,725 shares. Notably, Dr. Sally Bennett has been appointed to the Supervisory Board and will also serve on the Audit Committee. She brings over 20 years of experience in finance and life sciences. Additionally, Mr. Patrick Langlois has resigned from the Board after 12 years of service.